Tracking the Source of the Hepatitis B Virus–Specific CD8 T Cells during Lamivudine Treatment | Zendy

Fabio Malacarne | Zendy; George Webster | Zendy; Stephanie Reignat | Zendy; Jim Gotto | Zendy; Shahriar Behboudi | Zendy; Andrew K. Burroughs | Zendy; Geoffrey Dusheiko | Zendy; Roger Williams | Zendy; Antonio Bertoletti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tracking the Source of the Hepatitis B Virus–Specific CD8 T Cells during Lamivudine Treatment

Author(s) -

Fabio Malacarne,

George Webster,

Stephanie Reignat,

Jim Gotto,

Shahriar Behboudi,

Andrew K. Burroughs,

Geoffrey Dusheiko,

Roger Williams,

Antonio Bertoletti

Publication year - 2003

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/368369

Subject(s) - lamivudine , hepatitis b virus , cytotoxic t cell , lymph , hepatitis b , lymph node , cd8 , virology , immunology , medicine , virus , antigen , biology , in vitro , pathology , biochemistry

Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes. To address this question, the frequency and function of liver-, lymph node-, and blood-derived hepatitis B virus (HBV)-specific CD8 T cells were analyzed in patients treated with lamivudine and undergoing liver transplantation. HBV-specific CD8 T cells, identified in portal lymph nodes, were able to expand in vitro after antigen-specific stimulation and displayed a heterogeneous profile of cytokine production. These findings suggest that the peripherally reconstituted HBV-specific CD8 T cells can originate from precursor cells within lymph nodes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research